Literature DB >> 27296904

Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations.

Tiago A Mestre1, Erik van Duijn2, Aileen M Davis3, Anne-Catherine Bachoud-Lévi4, Monica Busse5, Karen E Anderson6, Joaquim J Ferreira7, Philipp Mahlknecht8, Vitor Tumas9, Cristina Sampaio10, Chris G Goetz11, Esther Cubo12, Glenn T Stebbins11, Pablo Martinez-Martin13.   

Abstract

Behavioral symptoms are an important feature of Huntington's disease and contribute to impairment in quality of life. The Movement Disorder Society commissioned the assessment of the clinimetric properties of rating scales in Huntington's disease to make recommendations regarding their use, following previously used standardized criteria. A systematic literature search was conducted to identify the scales used to assess behavioral symptoms in Huntington's disease. For the purpose of this review, 7 behavioral domains were deemed significant in Huntington's disease: irritability, anxiety, depression, apathy, obsessive-compulsive behaviors, psychosis, and suicidal ideation. We included a total of 27 behavioral rating scales, 19 of which were of a single behavioral domain and the remaining 8 scales included multiple behavioral domains. Three rating scales were classified as "recommended" exclusively for screening purposes: the Irritability Scale for irritability, the Beck Depression Inventory-II, and the Hospital Anxiety and Depression Scale for depression. There were no "recommended" scales for other purposes such as diagnosis, severity, or change in time or to treatment. The main challenges identified for assessment of behavioral symptoms in Huntington's disease are the co-occurrence of multiple behavioral symptoms, the particular features of a behavioral symptom in Huntington's disease, and the need to address stage- and disease-specific features, including cognitive impairment and lack of insight. The committee concluded that there is a need to further validate currently available behavioral rating scales in Huntington's disease to address gaps in scale validation for specific behavioral domains and purpose of use.
© 2016 International Parkinson and Movement Disorder Society. © 2016 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Huntington's disease; anxiety; behavior; depression; irritability; rating scales

Mesh:

Year:  2016        PMID: 27296904     DOI: 10.1002/mds.26675

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  12 in total

1.  Validation of Neuro-QoL and PROMIS Mental Health Patient Reported Outcome Measures in Persons with Huntington Disease.

Authors:  Noelle E Carlozzi; Siera Goodnight; Anna L Kratz; Julie C Stout; Michael K McCormack; Jane S Paulsen; Nicholas R Boileau; David Cella; Rebecca E Ready
Journal:  J Huntingtons Dis       Date:  2019

2.  The risks of converting post-hoc findings into primary outcomes in subsequent trials.

Authors:  Filipe B Rodrigues; Joaquim J Ferreira
Journal:  Ann Transl Med       Date:  2019-12

3.  Multidimensional Apathy: The Utility of the Dimensional Apathy Scale in Huntington's Disease.

Authors:  Kelly J Atkins; Sophie C Andrews; Trevor T-J Chong; Julie C Stout
Journal:  Mov Disord Clin Pract       Date:  2021-02-12

4.  Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington's disease.

Authors:  Filipe B Rodrigues; Lauren M Byrne; Rosanna Tortelli; Eileanoir B Johnson; Peter A Wijeratne; Marzena Arridge; Enrico De Vita; Naghmeh Ghazaleh; Richard Houghton; Hannah Furby; Daniel C Alexander; Sarah J Tabrizi; Scott Schobel; Rachael I Scahill; Amanda Heslegrave; Henrik Zetterberg; Edward J Wild
Journal:  Sci Transl Med       Date:  2020-12-16       Impact factor: 17.956

5.  Bupropion for the treatment of apathy in Huntington's disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial.

Authors:  Harald Gelderblom; Torsten Wüstenberg; Tim McLean; Lisanne Mütze; Wilhelm Fischer; Carsten Saft; Rainer Hoffmann; Sigurd Süssmuth; Peter Schlattmann; Erik van Duijn; Bernhard Landwehrmeyer; Josef Priller
Journal:  PLoS One       Date:  2017-03-21       Impact factor: 3.240

Review 6.  Rating Scales for Movement Disorders With Sleep Disturbances: A Narrative Review.

Authors:  Carmen Rodríguez-Blázquez; Maria João Forjaz; Monica M Kurtis; Roberta Balestrino; Pablo Martinez-Martin
Journal:  Front Neurol       Date:  2018-06-07       Impact factor: 4.003

7.  The use of wearable/portable digital sensors in Huntington's disease: A systematic review.

Authors:  Rosanna Tortelli; Filipe B Rodrigues; Edward J Wild
Journal:  Parkinsonism Relat Disord       Date:  2021-01-12       Impact factor: 4.891

8.  Montreal Cognitive Assessment (MoCA) performance in Huntington's disease patients correlates with cortical and caudate atrophy.

Authors:  Gabriel Ramirez-Garcia; Victor Galvez; Rosalinda Diaz; Aurelio Campos-Romo; Juan Fernandez-Ruiz
Journal:  PeerJ       Date:  2022-04-04       Impact factor: 2.984

Review 9.  Irritability in Huntington's Disease.

Authors:  Nicholas E Karagas; Natalia Pessoa Rocha; Erin Furr Stimming
Journal:  J Huntingtons Dis       Date:  2020

10.  Utility of Huntington's Disease Assessments by Disease Stage: Floor/Ceiling Effects.

Authors:  Daisy Abreu; Jennifer Ware; Nellie Georgiou-Karistianis; Blair R Leavitt; Cheryl J Fitzer-Attas; Raquel Lobo; Ana Raquel Fernandes; Olivia Handley; Karen E Anderson; Julie C Stout; Cristina Sampaio
Journal:  Front Neurol       Date:  2021-07-15       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.